Journal article · 2022 · Open access
CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection
PLoS Pathogens, 18(2), e1009831 · Published 7 February 2022 · DOI 10.1371/journal.ppat.1009831
In brief
“CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection” is a 2022 journal article by Mary S. Pampusch and 11 co-authors, published in PLoS Pathogens. OpenAlex counts 48 citations as of 19 November 2026, which puts it in the top 2% of works published in 2022 by citations. It is open access under a public domain licence: the full text is free to read at PLoS Pathogens.
- Citations
- 48
- Most cited in
- 2024 (12)
- Field-weighted impact
- 2.74
- References
- 117
- Authors
- 12
Abstract
During chronic human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV) infection prior to AIDS progression, the vast majority of viral replication is concentrated within B cell follicles of secondary lymphoid tissues. We investigated whether infusion of T cells expressing an SIV-specific chimeric antigen receptor (CAR) and the follicular homing receptor, CXCR5, could successfully kill viral-RNA + cells in targeted lymphoid follicles in SIV-infected rhesus macaques. In this study, CD4 and CD8 T cells from rhesus macaques were genetically modified to express antiviral CAR and CXCR5 moieties (generating CAR/CXCR5-T cells) and autologously infused into a chronically infected animal. At 2 days post-treatment, the CAR/CXCR5-T cells were located primarily in spleen and lymph nodes both inside and outside of lymphoid follicles. Few CAR/CXCR5-T cells were detected in the ileum, rectum, and lung, and no cells were detected in the bone marrow, liver, or brain. Within follicles, CAR/CXCR5-T cells were found in direct contact with SIV-viral RNA + cells. We next infused CAR/CXCR5-T cells into ART-suppressed SIV-infected rhesus macaques, in which the animals were released from ART at the time of infusion. These CAR/CXCR5-T cells replicated in vivo within both the extrafollicular and follicular regions of lymph nodes and accumulated within lymphoid follicles. CAR/CXR5-T cell concentrations in follicles peaked during the first week post-infusion but declined to undetectable levels after 2 to 4 weeks. Overall, CAR/CXCR5-T cell-treated animals maintained lower viral loads and follicular viral RNA levels than untreated control animals, and no outstanding adverse reactions were noted. These findings indicate that CAR/CXCR5-T cell treatment is safe and holds promise as a future treatment for the durable remission of HIV.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Pampusch, M. S., Abdelaal, H. M., Cartwright, E. K., Molden, J. S., Davey, B. C., Sauve, J. D., Sevcik, E. N., Rendahl, A., Rakasz, E. G., Connick, E., Berger, E. A., & Skinner, P. J. (2022). CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection. PLoS Pathogens, 18(2), e1009831. https://doi.org/10.1371/journal.ppat.1009831
MLA 9
Pampusch, Mary S., et al. “CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.” PLoS Pathogens, vol. 18, no. 2, 2022, p. e1009831. https://doi.org/10.1371/journal.ppat.1009831.
Chicago
Pampusch, Mary S., Hadia M. Abdelaal, Emily Kathleen Cartwright, Jhomary S. Molden, Brianna C. Davey, Jordan D. Sauve, Emily N. Sevcik, et al. 2022. “CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.” PLoS Pathogens 18 (2): e1009831. https://doi.org/10.1371/journal.ppat.1009831.
Harvard
Pampusch, M. S. et al. (2022) ‘CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection’, PLoS Pathogens, 18(2), p. e1009831. doi:10.1371/journal.ppat.1009831.
IEEE
M. S. Pampusch et al., “CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection,” PLoS Pathogens, vol. 18, no. 2, p. e1009831, 2022, doi: 10.1371/journal.ppat.1009831.
BibTeX
@article{pampusch2022cxcr,
title = {{CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection}},
author = {Pampusch, Mary S. and Abdelaal, Hadia M. and Cartwright, Emily Kathleen and Molden, Jhomary S. and Davey, Brianna C. and Sauve, Jordan D. and Sevcik, Emily N. and Rendahl, Aaron and Rakasz, Eva G. and Connick, Elizabeth and Berger, Edward A. and Skinner, Pamela J.},
journal = {PLoS Pathogens},
year = {2022},
volume = {18},
number = {2},
pages = {e1009831},
doi = {10.1371/journal.ppat.1009831},
url = {https://doi.org/10.1371/journal.ppat.1009831}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 9 | |
| 2023 | 7 | |
| 2024 | 12 | |
| 2025 | 9 | |
| 2026 | 11 |
Its field-weighted citation impact is 2.74: it has been cited 2.74 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- chimeric antigen receptor
- CXCR5
- SIV infection
- simian immunodeficiency virus
- HIV remission
- chronic HIV infection
- rhesus monkeys
- B cell follicles
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Pampusch, M. S., Abdelaal, H. M., Cartwright, E. K., Molden, J. S., Davey, B. C., Sauve, J. D., Sevcik, E. N., Rendahl, A., Rakasz, E. G., Connick, E., Berger, E. A., & Skinner, P. J. (2022). CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection. PLoS Pathogens, 18(2), e1009831. https://doi.org/10.1371/journal.ppat.1009831
How many times has this paper been cited?
48 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PLoS Pathogens: sign in and open the PDF from this page.
Who wrote this paper?
Mary S. Pampusch, Hadia M. Abdelaal, Emily Kathleen Cartwright, Jhomary S. Molden, Brianna C. Davey, Jordan D. Sauve, Emily N. Sevcik, Aaron Rendahl, Eva G. Rakasz, Elizabeth Connick, Edward A. Berger, Pamela J. Skinner.
What is the DOI of this paper?
10.1371/journal.ppat.1009831, permanently at https://doi.org/10.1371/journal.ppat.1009831. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.